The Enterprise Value as of December 2025 (TTM) for 4D Molecular Therapeutics, Inc. (FDMT) is 496.31M

According to 4D Molecular Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 496.31M. This represents a change of 130.58% compared to the average of 215.24M of the last 4 quarters.

4D Molecular Therapeutics, Inc. (FDMT) Historical Enterprise Value (quarterly & annually)

How has FDMT Enterprise Value performed in the past?

The mean historical Enterprise Value of 4D Molecular Therapeutics, Inc. over the last ten years is 570.84M. The current 496.31M Enterprise Value has changed 8.59% with respect to the historical average. Over the past ten years (40 quarters), FDMT's Enterprise Value was at its highest in in the March 2024 quarter at 1.22B. The Enterprise Value was at its lowest in in the June 2018 quarter at 0.

4D Molecular Therapeutics, Inc. (FDMT) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of 4D Molecular Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

4D Molecular Therapeutics, Inc. (FDMT) Average Enterprise Value

How has FDMT Enterprise Value performed in the past?

The current Enterprise Value of 4D Molecular Therapeutics, Inc. (FDMT) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

4D Molecular Therapeutics, Inc. (FDMT) Enterprise Value vs. Peers

How is FDMT’s Enterprise Value compared to its peers?

4D Molecular Therapeutics, Inc.’s Enterprise Value is less than KalVista Pharmaceuticals, Inc. (710.80M), less than Omeros Corporation (883.69M), greater than Bicycle Therapeutics plc (-152624053.00), less than Gossamer Bio, Inc. (930.39M), less than Lexicon Pharmaceuticals, Inc. (556.11M), greater than ADC Therapeutics S.A. (262.56M), greater than Neumora Therapeutics, Inc. Common Stock (251.41M), less than REGENXBIO Inc. (674.74M), greater than Prothena Corporation plc (278.98M), less than Compass Therapeutics, Inc. (719.89M),

Build a custom stock screener for 4D Molecular Therapeutics, Inc. (FDMT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 4D Molecular Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

4D Molecular Therapeutics, Inc. (FDMT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like 4D Molecular Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.